The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer-Reference-Cited by-同舟云学术

The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer

Published:2024-06-19 Issue:1 Volume:10 Page:
ISSN:2374-4677
Container-title:npj Breast Cancer
language:en
Short-container-title:npj Breast Cancer

Author:

Johnson Kai C. C.,Ni Ai,Quiroga Dionisia^ORCID,Pariser Ashley C.,Sudheendra Preeti K.,Williams Nicole O.,Sardesai Sagar D.,Cherian Mathew,Stover Daniel G.^ORCID,Gatti-Mays Margaret^ORCID,Ramaswamy Bhuvaneswari^ORCID,Lustberg Maryam,Jhawar Sachin,Skoracki Roman,Wesolowski Robert^ORCID

Abstract

AbstractThere is limited data regarding the added benefit of adjuvant systemic therapy in the management of small, node-negative, HER2+ breast cancer. In a multi-institutional retrospective analysis using the American Society of Clinical Oncology CancerLinQ database, we compared survival outcomes among T1a-c N0 HER2+ patients diagnosed between 2010 to 2021 who received locoregional therapy alone or in combination with adjuvant trastuzumab (+/− chemotherapy). Primary outcomes were invasive disease-free survival (iDFS) and overall survival (OS). Of the 1,184 patients, 436 received locoregional therapy alone. We found a statistically significant improvement in iDFS (HR 0.73, P = 0.003) and OS (HR 0.63, P = 0.023) on univariate analysis with adjuvant trastuzumab with or without chemotherapy which remained statistically significant on multivariate analysis. Three-arm univariate analysis found that iDFS was significantly improved with trastuzumab monotherapy (P = 0.003) and combination therapy (P = 0.027) compared to observation. Subgroup data suggests that T1b/c tumors derive the greatest benefit.

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41523-024-00652-4.pdf

Reference31 articles.

1. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).

2. Moasser, M. M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26, 6469–6487 (2007).

3. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl. J. Med. 344, 783–792 (2001).

4. Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl. J. Med. 353, 1673–1684 (2005).

5. Piccart-Gebhart, M. J. et al. Herceptin adjuvant (HERA) trial study team. trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New Engl. J. Med. 353, 1659–1672 (2005).